Voyager Therapeutics Inc. operates as a biotechnology company focusing on developing gene therapies for severe neurological diseases and other disorders. The company's primary purpose is to harness the potential of gene therapy to transform the treatment landscape for conditions that have limited therapeutic options, such as Parkinson’s disease, Huntington’s disease, and various forms of neuropathy. Notable features of Voyager Therapeutics include its robust pipeline of preclinical and clinical-stage programs that utilize its proprietary AAV capsid engineering and delivery technology. This technology aims to optimize the targeting and expression of therapeutic genes in specific areas of the central nervous system. As an integral player in the biotech industry, Voyager Therapeutics contributes significant advancements in the field of precision medicine, offering potential new avenues for treatment where conventional methods may fall short. Headquartered in Cambridge, Massachusetts, the company positions itself at the forefront of therapeutic innovation, collaborating with leading pharmaceutical companies to accelerate the development and commercialization of groundbreaking therapies.